PCCS

C&W Networks Upgrades CFX-1 and EWC Submarine Cables with Ciena

Retrieved on: 
Monday, September 26, 2022

These network upgrades will help address the soaring bandwidth needs of C&W Networks telco and internet service provider (ISP) customers.

Key Points: 
  • These network upgrades will help address the soaring bandwidth needs of C&W Networks telco and internet service provider (ISP) customers.
  • C&W Networks operates the largest submarine multi-ring fiber-optic network in the greater Caribbean, Central American and Andean regions, providing reliable connectivity to approximately 40 countries.
  • C&W Networks submarine cables cross the ocean to bring the pan-Caribbean region new opportunities and economic growth through connectivity, said Ian Clarke, Vice President of Global Submarine Solutions, Ciena.
  • For updates on Ciena, follow us on Twitter @Ciena , LinkedIn , the Ciena Insights blog , or visit www.ciena.com .

Postmaster General DeJoy Addresses Nation's Commercial Mailers

Retrieved on: 
Friday, September 23, 2022

WASHINGTON, Sept. 23, 2022 /PRNewswire/ -- In a keynote video address this week to partnership groups composed of Postal Service leaders and the nation's commercial mailers, USPS Postmaster General and CEO Louis DeJoy said the Postal Service is a different organization now than when he arrived more than two years ago.

Key Points: 
  • WASHINGTON, Sept. 23, 2022 /PRNewswire/ -- In a keynote video address this week to partnership groups composed of Postal Service leaders and the nation's commercial mailers, USPS Postmaster General and CEO Louis DeJoy said the Postal Service is a different organization now than when he arrived more than two years ago.
  • DeJoy said, "One of the biggest initiatives under Delivering for America is empowering employees to embrace the changes that are needed to succeed.
  • We need your operating and marketing prowess and your competitive spirit to help us win together in the marketplace," DeJoy said.
  • The mission of the PCC is to foster a close working relationship between the Postal Service and commercial mailers.

Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs

Retrieved on: 
Thursday, September 1, 2022

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the companys official listing on the Main Board of the Stock Exchange of Hong Kong.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the companys official listing on the Main Board of the Stock Exchange of Hong Kong.
  • The company harnesses these specialized models to provide preclinical pharmacology evaluation services for global pharmaceutical/biotech companies.
  • Biocytogen strives to become the headstream of novel antibody drugs.
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies.

Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs

Retrieved on: 
Thursday, September 1, 2022

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the companys official listing on the Main Board of the Stock Exchange of Hong Kong.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the companys official listing on the Main Board of the Stock Exchange of Hong Kong.
  • The company harnesses these specialized models to provide preclinical pharmacology evaluation services for global pharmaceutical/biotech companies.
  • Biocytogen strives to become the headstream of novel antibody drugs.
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies.

Petal Maps Debuts at MWC 2022, Showcasing a Full-Scenario Ecosystem with Mapping Services as the Core

Retrieved on: 
Friday, March 4, 2022

With its leading UI design interactive experience, Petal Maps won the 2021 German Red Dot Design Award.

Key Points: 
  • With its leading UI design interactive experience, Petal Maps won the 2021 German Red Dot Design Award.
  • With this release, Petal Maps launches travel guides that include comprehensive and detailed information on Barcelona's hotels, restaurants, museums and other points of interest.
  • Petal Maps has also integrated its own mapping and positioning capabilities providing rich one-stop mapping service solutions to empower developers and partners.
  • Petal Maps plans to continue enriching the platform's capabilities, identify and integrate new cutting-edge technologies as well as collaborate with leaders in navigation technology to further perfect the mapping ecosystem and enhance the user experience.

Petal Maps Debuts at MWC 2022, Showcasing a Full-Scenario Ecosystem with Mapping Services as the Core

Retrieved on: 
Friday, March 4, 2022

Petal Maps highlights the color contrast between different regions and routes, distinguishes cities from suburbs while visually showing the differentiation in altitude between adjacent roads.

Key Points: 
  • Petal Maps highlights the color contrast between different regions and routes, distinguishes cities from suburbs while visually showing the differentiation in altitude between adjacent roads.
  • With its leading UI design interactive experience, Petal Maps won the 2021 German Red Dot Design Award.
  • With this release, Petal Maps launches travel guides that include comprehensive and detailed information on Barcelona's hotels, restaurants, museums and other points of interest.
  • Petal Maps has also integrated its own mapping and positioning capabilities providing rich one-stop mapping service solutions to empower developers and partners.

Small Molecule Targeting CD47-SIRPα Pathway: Insilico Medicine Achieves its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL

Retrieved on: 
Thursday, February 17, 2022

Notably, this is the first major milestone achieved by Insilico in the strategic collaboration with Fosun Pharma.

Key Points: 
  • Notably, this is the first major milestone achieved by Insilico in the strategic collaboration with Fosun Pharma.
  • Insilico Medicine and Fosun Pharma are working together on IND-enabling studies to advance PCCs in the QPCTL program to clinical trials.
  • ISM004-1057D, Insilico's first PCC for its QPCTL program, is a potential first-in-class small molecule inhibitor that targets QPCTL.
  • As a small molecule inhibitor of QPCTL, ISM004-1057D not only provides high tumor penetration but also reduces potential hematologic and antigen sink side effects.

Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation

Retrieved on: 
Wednesday, January 5, 2022

ISM012-042 is potentially a first-in-class gut-restricted PHD2 inhibitor for IBD treatment that induces the expression of gut barrier protective genes.

Key Points: 
  • ISM012-042 is potentially a first-in-class gut-restricted PHD2 inhibitor for IBD treatment that induces the expression of gut barrier protective genes.
  • "Anemia and IBD affect large patient populations that are in urgent need of efficacious and safe drugs," said Feng Ren, Ph.D., CSO of Insilico Medicine.
  • Empowered by its AI-based platform, Chemistry42, Insilico Medicine synthesized and tested approximately 115 compounds in total and discovered both PCCs within 12 months of project initiation.
  • "It took 12 months from program initiation to the nomination of preclinical candidates, including the completion of supporting animal studies for both anemia and IBD, demonstrating the power of Insilico's AI platform."

Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation

Retrieved on: 
Wednesday, January 5, 2022

ISM012-042 is potentially a first-in-class gut-restricted PHD2 inhibitor for IBD treatment that induces the expression of gut barrier protective genes.

Key Points: 
  • ISM012-042 is potentially a first-in-class gut-restricted PHD2 inhibitor for IBD treatment that induces the expression of gut barrier protective genes.
  • "Anemia and IBD affect large patient populations that are in urgent need of efficacious and safe drugs," said Feng Ren, Ph.D., CSO of Insilico Medicine.
  • Empowered by its AI-based platform, Chemistry42, Insilico Medicine synthesized and tested approximately 115 compounds in total and discovered both PCCs within 12 months of project initiation.
  • "It took 12 months from program initiation to the nomination of preclinical candidates, including the completion of supporting animal studies for both anemia and IBD, demonstrating the power of Insilico's AI platform."

Captive insurance to be a primary focus in Labuan IBFC's 5-year strategic roadmap

Retrieved on: 
Friday, December 3, 2021

KUALA LUMPUR, Malaysia, Dec. 3, 2021 /PRNewswire/ -- Labuan International Business and Financial Centre (Labuan IBFC) continues to expand with increasing demand for its varying captive structures from across the globe, charting a 28% increase in its premiums for captive business and 18 new captives approved as at the third quarter of 2021.

Key Points: 
  • "At the same time, the Labuan captive business model which utilises protected cell companies (PCCs) has gained traction as a cost-effective method of operating captives.
  • To date, there are approximately 7,000 captive insurance companies set up globally that enjoy this benefit.
  • Established in 1990, Labuan IBFC is regulated by the Labuan Financial Services Authority (Labuan FSA), statutory Regulator under the purview of the Ministry of Finance, Malaysia.
  • To keep up with everything about Labuan IBFC, follow us on LinkedIn, Facebook or Twitter @LabuanIBFC.